The genetics of castration-resistant prostate cancer: What can the germlinetell us?

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4691-4693

  Sharifi, Nima ^a,b   Dahut, William L ^a,b   Figg, William D ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; AROMATASE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN METABOLISM; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DNA POLYMORPHISM; GENE; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GLEASON SCORE; HSD17B4 GENE; HUMAN; METASTASIS; OATPIB3 GENE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B3 GENE; TREATMENT RESPONSE; ANIMAL; BIOLOGICAL MODEL; CLINICAL TRIAL; DRUG RESISTANCE; GENETICS; MALE; METABOLISM; PROSTATE TUMOR; REVIEW;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 51049092294     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0453     Document Type: Short Survey

References (22)

1. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15.
2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294: 238-44.
3. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289-95.
4. Bolla M, Descotes JL, Artignan X, Fourneret P. Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer. BJU Int 2007;100 Suppl 2:44-7.
5. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
6. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984-90.
7. DePrimo SE, Diehn M. Nelson JB, et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 2002:3 RESEARCH0032.
8. Mousses S, Wagner U, Chen Y, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001; 20:6718-23.
9. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
10. Sharifi N, Farrar WL Androgen receptor as a therapeutic target for androgen independent prostate cancer. Am J Ther 2006;13:166-70.
11. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
12. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552-6.
13. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25.
14. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
15. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007;28:778-808.
16. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCa P cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-40.
17. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
18. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11: 4653-7.
19. Ross RW, Oh WK, Xie W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008;26:842-7.
20. Hamada A, Sissung T, Price P, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008;14:3312-8.
21. Smith NF, Marsh S, Scott-Horton TJ, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76-82.
22. Sharifi N, Hamada A, Sissung T, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int. Epub 2008 Jun 4.